Cover Image
市場調查報告書

主要先進國家市場的非何傑金氏淋巴瘤(NHL)治療藥市場:由於新企業加入和有潛力開發平台的標的·免疫療法選擇

Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options

出版商 GBI Research 商品編碼 318232
出版日期 內容資訊 英文 109 Pages
訂單完成後即時交付
價格
Back to Top
主要先進國家市場的非何傑金氏淋巴瘤(NHL)治療藥市場:由於新企業加入和有潛力開發平台的標的·免疫療法選擇 Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options
出版日期: 2014年10月31日 內容資訊: 英文 109 Pages
簡介

主要先進國家市場的非何傑金氏淋巴瘤(NHL)治療藥市場,預測將從2013年的56億美元,以CAGR7.4%的速度成長,到2020年將擴大到92億美元的規模。

本報告提供主要先進國家市場的非何傑金氏淋巴瘤(NHL)治療藥市場相關調查分析,提供您市場概要,上市產品,開發中產品,市場預測,交易和策略性整合等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 症狀
  • 病因
  • 病理學
  • 診斷
  • 分類
  • 流行病學
  • 預後與疾病的重病度
  • 治療的選項

第3章 上市產品

  • 治療情形
  • 標的/免疫療法
  • 化療/Regimens
  • 有效性和安全性比較(上市產品)

第4章 開發中產品

  • 開發平台全體
  • 開發平台分析:各分子類型
  • 開發平台分析:各作用機制
  • 臨床試驗
  • 開發平台的有潛力候補藥劑
    • BiovaxID (dasiprotimut T)
    • Alisertib (MLN8237)
    • Arzerra (ofatumumab)
    • Gazyva (obinutuzumab)
    • Afinitor (everolimus)
  • 開發中產品的安全性和有效性的熱圖,產品競爭力的組成架構

第5章 市場預測

  • 各地區市場
    • 全球市場
    • 北美
    • EU主要5個國家
    • 日本
  • 推動市場要素與阻礙
    • 推動因素
    • 障礙

第6章 交易與策略性整合

  • 主要的共同開發交易
  • 主要的許可證交易

第7章 附錄

圖表

目錄
Product Code: GBIHC343MR

Summary

GBI Research, a leading business intelligence provider, has released its latest research report, "Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options", which provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan and Canada. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).

The value of the NHL market is expected to reach $9.2 billion by 2020 from $5.6 billion in 2013 at a modest Compound Annual Growth Rate (CAGR) of 7.4%. The expected launch of promising drugs, including novel small molecule inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera (rituximab), will be the key growth drivers. The launch of a premium-priced novel glycol-engineered antibody; obinutuzumab; the personalized vaccine dasiprotimut-T, mTOR inhibitor everolimus, and several kinase inhibitors including idelalisib and ibrutinib (which already gained FDA approval) are expected to have a significant impact on the market size. Additionally, the extension of indications of several already marketed drugs such as Revlimid as a maintenance therapy for DLBCL, Velcade as a front-line therapy for MCL and Adcetris as front-line therapy for CD30 T-cell lymphoma, will fuel the growth during the forecast period.

The emerging treatment challenges in the current treatment landscape (which include, treatment of refractory/relapsed disease and increasing rituximab resistance) are expected to be addressed by the promising NHL pipeline. In spite of a slew of expected approvals the market is set to increase a modest pace due to the patent expiry of the gold-standard therapy during the forecast period.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. It includes -

  • A brief introduction to NHL, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms
  • In-depth analysis of currently marketed drugs for NHL, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
  • A comprehensive review of the pipeline for NHL, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
  • Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the NHL market since 2006

Reasons to buy

The report will enhance your decision-making capability by allowing you to -

  • Understand the NHL pipeline and the factors that indicate that it is becoming more innovative
  • Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
  • Follow the trends in NHL clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
  • Observe the potential growth patterns expected for the NHL market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the NHL market
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Symptoms
  • 2.2. Etiology
  • 2.3. Pathophysiology
  • 2.4. Diagnosis
    • 2.4.1. Biopsy
    • 2.4.2. Laboratory molecular tests
    • 2.4.3. Imaging tests
  • 2.5. Classification
    • 2.5.1. B-Cell Lymphomas
    • 2.5.2. T-Cell Lymphoma
  • 2.6. Epidemiology
  • 2.7. Prognosis and Disease Staging
    • 2.7.1. Staging
  • 2.8. Treatment Options
    • 2.8.1. Surgery and Radiation Therapy
    • 2.8.2. Stem Cell Transplantation
    • 2.8.3. Pharmacological
    • 2.8.4. Treatment Algorithms and Prescribing Habits

3. Marketed Products

  • 3.1. Therapeutic Landscape
  • 3.2. Targeted/Immunotherapies
    • 3.2.1. Rituxan/Mabthera (rituximab) - Roche
    • 3.2.2. Adcetris (Brentuximab vedotin) - Seattle Genetics/Millennium
    • 3.2.3. Zevalin (ibritumomab tiuxetan) - Spectrum Pharmaceuticals
    • 3.2.4. Revlimid (lenalidomide) - Celgene
    • 3.2.5. Velcade (bortezomib) - Millennium/Johnson-Johnson
    • 3.2.6. Istodax (romidepsin) - Celgene
    • 3.2.7. Zolinza (vorinostat) - Merck
    • 3.2.8. Zydelig (idelalisib/GS-1101) - Gilead Sciences
    • 3.2.9. Imbruvica (ibrutinib) - Pharmacyclics/Janssen Biotech
    • 3.2.10. Beleodaq (belinostat) - Spectrum Pharmaceuticals
    • 3.2.11. Poteligeo (mogamulizumab) - Kyowa Hakko Kirin
  • 3.3. Chemotherapies/Regimens
    • 3.3.1. Pixuvri (pixantrone dimaleate) - CTI BioPharma
    • 3.3.2. Treanda (bendamustine) + Rituxan (rituximab)
    • 3.3.3. CHOP/R-CHOP
    • 3.3.4. CVP/R-CVP
  • 3.4. Comparative Efficacy and Safety (Marketed Products)

4. Pipeline Products

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecule Type
  • 4.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate
    • 4.4.2. Patient Enrollment and Clinical Trial Size
    • 4.4.3. Duration
  • 4.5. Promising Drug Candidates in the Pipeline
    • 4.5.1. BiovaxID (dasiprotimut T) - Biovest International
    • 4.5.2. Alisertib (MLN8237) - Millennium Pharmaceuticals
    • 4.5.3. Arzerra (ofatumumab) - Genmab/GlaxoSmithKline
    • 4.5.4. Gazyva (obinutuzumab) - Roche
    • 4.5.5. Afinitor (everolimus) - Novartis
  • 4.6. Heat Map of Safety and Efficacy and Product Competitiveness Framework for Non-Hodgkin Lymphoma Pipeline

5. Market Forecast to 2020

  • 5.1. Geographical Markets
    • 5.1.1. Global Market
    • 5.1.2. North America
    • 5.1.3. Top Five EU Countries
    • 5.1.4. Japan
  • 5.2. Drivers and Barriers for the Disease Market
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Major Co-development Deals
    • 6.1.1. Roche Signs an Agreement with GlycArt and Genentech
    • 6.1.2. Cell Therapeutics Enters Agreement with Bayer
    • 6.1.3. Chugai Enters Co-development Agreement with Nippon Shinyaku for GA101
    • 6.1.4. GlaxoSmithKline Enters Co-development Agreement with Genmab
    • 6.1.5. Biogen Idec Enters Co-development Agreement with Genentech
    • 6.1.6. Seattle Genetics Enters Co-development Agreement with Millennium
  • 6.2. Major Licensing Deals
    • 6.2.1. Spectrum Enters Licensing Agreement with Bayer for Zevalin
    • 6.2.2. Janssen Biotech Enters Licensing Agreement with Pharmacyclics for PCI-32765
    • 6.2.3. Lundbeck Enters Licensing Agreement with Cephalon
    • 6.2.4. TG Therapeutics Enters Licensing Agreement with Ildong for Ublituximab
    • 6.2.5. Provenance Enters Licensing Agreement with Merck Serono
    • 6.2.6. Cephalon Enters Licensing Agreement with SymBio
    • 6.2.7. Genentech Enters Licensing Agreement with Seattle Genetics

7. Appendix

  • 7.1. Market Definitions
  • 7.2. Abbreviations
  • 7.3. Bibliography
  • 7.4. Pipeline Tables
    • 7.4.1. Discovery
    • 7.4.2. Preclinical
    • 7.4.3. Investigational New Drug-Filed
    • 7.4.4. Phase I
    • 7.4.5. Phase II
    • 7.4.6. Phase III
  • 7.5. Market Forecasts to 2020
    • 7.5.1. Global
    • 7.5.2. US
    • 7.5.3. UK
    • 7.5.4. France
    • 7.5.5. Germany
    • 7.5.6. Italy
    • 7.5.7. Spain
    • 7.5.8. Canada
    • 7.5.9. Japan
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Non-Hodgkin Lymphoma Therapeutics, Most Common Chromosomal Aberrations Associated With NHL
  • Table 2: Non-Hodgkin Lymphoma Therapeutics, International Working Formulation Classification of Lymphoproliferative Diseases, 1981
  • Table 3: Non-Hodgkin Lymphoma Market, Classification of Non-Hodgkin Lymphoma
  • Table 4: Non-Hodgkin Lymphoma Market, Top Five European Countries, Incidence rates (per 100,000), 2012
  • Table 5: Non-Hodgkin Lymphoma Market, International Prognostic Index Good and Poor Prognostic Factors
  • Table 6: Non-Hodgkin Lymphoma Market, Ann Arbor Staging System for Lymphoma, 2013
  • Table 7: Non-Hodgkin Lymphoma Market, Commonly Used Chemo-Regimens
  • Table 8: Non-Hodgkin Lymphoma Market, Dosing Regime of Rituxan for Multiple Sub-types
  • Table 9: Non-Hodgkin Lymphoma Market, Endpoints of Various Chemotherapeutic Regimens (%), 1993
  • Table 10: Non-Hodgkin Lymphoma Market, Efficacy Comparison of R-CHOP vs. CHOP
  • Table 11: Non-Hodgkin Lymphoma Market, Efficacy Comparison of CVP vs. R-CVP, 2005
  • Table 12: Non-Hodgkin Lymphoma Market, Global, Average Clinical Trial Duration (Months)
  • Table 13: Non-Hodgkin Lymphoma Market, Top Five EU Countries, 5-Year Survival Rates (%), 2000-2007
  • Table 14: Non-Hodgkin Lymphoma Market, Global, Deals and Strategic Consolidations, 2006-2014
  • Table 15: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Discovery), 2014
  • Table 16: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Preclinical), 2014
  • Table 17: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (IND-filed), 2014
  • Table 18: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase I), 2014
  • Table 19: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase II), 2014
  • Table 20: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase III), 2014
  • Table 21: Non-Hodgkin Lymphoma Market, Global, Market Forecast, 2013-2020
  • Table 22: Non-Hodgkin Lymphoma Market, US, Market Forecast, 2013-2020
  • Table 23: Non-Hodgkin Lymphoma Market, UK, Market Forecast, 2013-2020
  • Table 24: Non-Hodgkin Lymphoma Market, Germany, Market Forecast, 2013-2020
  • Table 25: Non-Hodgkin Lymphoma Market, Germany, Market Forecast, 2013-2020
  • Table 26: Non-Hodgkin Lymphoma Market, Italy, Market Forecast, 2013-2020
  • Table 27: Non-Hodgkin Lymphoma Market, Spain, Market Forecast, 2013-2020
  • Table 28: Non-Hodgkin Lymphoma Market, Canada, Market Forecast, 2013-2020
  • Table 29: Non-Hodgkin Lymphoma Market, Japan, Market Forecast, 2013-2020

List of Figures

  • Figure 1: Non-Hodgkin Lymphoma Market, Global, Distribution of Prevalence Population ('000), 2013-2020
  • Figure 2: Non-Hodgkin Lymphoma Market, Treatment Algorithm for Indolent Non-Hodgkin Lymphoma, 2014
  • Figure 3: Non-Hodgkin Lymphoma Market, Treatment Algorithm for Aggressive Non-Hodgkin Lymphoma, 2014
  • Figure 4: Non-Hodgkin Lymphoma Market, Global, Rituxan, Annual Sales ($bn), 2006-2013
  • Figure 5: Non-Hodgkin Lymphoma Market, Global, Adcetris, Annual Sales ($m), 2011-2013
  • Figure 6: Non-Hodgkin Lymphoma Market, Global, Velcade, Annual Sales ($bn), 2007-2013
  • Figure 7: Non-Hodgkin Lymphoma Market, Global, Istodax, Annual Sales ($m), 2010-2013
  • Figure 8: Non-Hodgkin Lymphoma Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2014
  • Figure 9: Non-Hodgkin Lymphoma Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2014
  • Figure 10: Non-Hodgkin Lymphoma Market, Global, Pipeline by Molecule Type and Stage of Development, 2014
  • Figure 11: Non-Hodgkin Lymphoma Market, Global, Pipeline by Mechanism of Action, 2014
  • Figure 12: Non-Hodgkin Lymphoma, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2014
  • Figure 13: Non-Hodgkin Lymphoma Market, Global, Clinical Trial Failure Rate (%), 2014
  • Figure 14: Non-Hodgkin Lymphoma Market, Global, Clinical Trial Size (Participants), 2014
  • Figure 15: Non-Hodgkin Lymphoma Market, Global, Pipeline Clinical Trial Duration (Months), 2014
  • Figure 16: Non-Hodgkin Lymphoma Market, Global, Comparative Safety and Efficacy of Pipeline Products (Heat Map), 2014
  • Figure 17: Non-Hodgkin Lymphoma Market, Global, Treatment Use Pattern and Market Size, 2013-2020
  • Figure 18: Non-Hodgkin Lymphoma Market, North America, Treatment Use Pattern ('000), 2013-2020
  • Figure 19: Non-Hodgkin Lymphoma Market, North America, Annual Cost of Therapy ($), 2013-2020
  • Figure 20: Non-Hodgkin Lymphoma Market, North America, Market Size ($m), 2013-2020
  • Figure 21: Non-Hodgkin Lymphoma Market, Top Five EU Countries, Treatment Use Pattern ('000), 2013-2020
  • Figure 22: Non-Hodgkin Lymphoma Market, Top Five EU Countries, Annual Cost of Therapy ($'000), 2013-2020
  • Figure 23: Non-Hodgkin Lymphoma Market, Top Five EU Countries, Market Size ($m), 2013-2020
  • Figure 24: Non-Hodgkin Lymphoma Market, Japan, Treatment Use Pattern ('000), 2013-2020
  • Figure 25: Non-Hodgkin Lymphoma Market, Japan, Annual Cost of Therapy ($'000), 2013-2020
  • Figure 26: Non-Hodgkin Lymphoma Market, Japan, Market Size ($m), 2013-2020
  • Figure 27: Non-Hodgkin Lymphoma Market, Global Deals by Value, Year and Stage of Development, 2006-2014
  • Figure 28: Non-Hodgkin Lymphoma Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006-2014
  • Figure 29: Non-Hodgkin Lymphoma Market, Global, Co-development Deals by Geography, 2006-2014
  • Figure 30: Non-Hodgkin Lymphoma Market, Global, Licensing Deals by Geography, 2006-2014
  • Figure 31: GBI Research Market Forecasting Model (Example)
Back to Top